FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL
Publication
, Conference
Swords, RT; Savona, MR; Maris, MB; Erba, HP; Hua, Z; Faessel, H; Blakemore, SJ; Sedarati, F; Dezube, BJ; Medeiros, BC
Published in: HAEMATOLOGICA
June 1, 2014
Duke Scholars
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
June 1, 2014
Volume
99
Start / End Page
223 / 224
Location
Milan, ITALY
Publisher
FERRATA STORTI FOUNDATION
Conference Name
19th Congress of the European-Hematology-Association
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Swords, R. T., Savona, M. R., Maris, M. B., Erba, H. P., Hua, Z., Faessel, H., … Medeiros, B. C. (2014). FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL. In HAEMATOLOGICA (Vol. 99, pp. 223–224). Milan, ITALY: FERRATA STORTI FOUNDATION.
Swords, R. T., M. R. Savona, M. B. Maris, H. P. Erba, Z. Hua, H. Faessel, S. J. Blakemore, F. Sedarati, B. J. Dezube, and B. C. Medeiros. “FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL.” In HAEMATOLOGICA, 99:223–24. FERRATA STORTI FOUNDATION, 2014.
Swords RT, Savona MR, Maris MB, Erba HP, Hua Z, Faessel H, et al. FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2014. p. 223–4.
Swords, R. T., et al. “FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL.” HAEMATOLOGICA, vol. 99, FERRATA STORTI FOUNDATION, 2014, pp. 223–24.
Swords RT, Savona MR, Maris MB, Erba HP, Hua Z, Faessel H, Blakemore SJ, Sedarati F, Dezube BJ, Medeiros BC. FIRST-IN-CLASS NAE INHIBITOR MLN4924 IN COMBINATION WITH AZACITIDINE FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS CONSIDERED UNFIT FOR CONVENTIONAL CHEMOTHERAPY: RESULTS FROM THE C15009 TRIAL. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2014. p. 223–224.
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
June 1, 2014
Volume
99
Start / End Page
223 / 224
Location
Milan, ITALY
Publisher
FERRATA STORTI FOUNDATION
Conference Name
19th Congress of the European-Hematology-Association
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology